Study of Patient With Frequent COPD Exacerbations
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
2,038actual
Sites
6
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-16 | actual | When the study began enrolling |
| Primary completion | 2026-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease (COPD)
Primary outcomes
what the primary-completion date above is the date OFTo describe the baseline Demographic data characterisics of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline Negative lifestyle factors characterisics of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline Anthropometry data characterisics of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline COPD drug treatment duration in previous 52 weeks of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline Cardiovascular diseases of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline other comorbidities of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline Blood eosinophils count of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline mean smoking index .
measured 52 weeks of retrospective data before visit 1
To describe the baseline mean duration of smoking
measured 52 weeks of retrospective data before visit 1
To describe the Proportion of patients with overweight
measured 52 weeks of retrospective data before visit 1
To describe the baseline dosages of COPD drug treatment in previous 52 weeks of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with heart failure of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline data of LVEF of patients with heart failure of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with each CKD stage - C1, C2, C3a, C3b, C4, C5 of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline mean office BP (SBP and DBP) measured at Visit 1 of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with AH by distribution by AH stage (I, II, III), AH degree (1st, 2nd, 3rd) and risk category at Visit 1 of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with various classes of medications used for treatment of CVD of outpatients with moderate and severe COPD.
measured 52 weeks of retrospective data before visit 1
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed